Clinical Trials Logo
  1. Home
  2. Diabetes Mellitus, Type 2
  3. NCT06245980
  4. Details
NCT06245980 Clinical Trial

Role of SGLT2I in Patients With Myocardial Infarction

Diabetes Mellitus Clinical Trial

Official title:
Role of SGLT2I in Diabetic Patients With Myocardial Infarction

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06245980
Other study ID # 20230515
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2018
Est. completion date March 31, 2024

Study information
Verified date May 2023
Source Chongqing Medical University
Contact xuesong wen
Phone +8618702384027
Email 1979272415@qq.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Role of sglt2I in diabetic patients with myocardial infarction

Recruitment information / eligibility
Status Recruiting
Enrollment 1200
Est. completion date March 31, 2024
Est. primary completion date February 28, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: 1. Acute myocardial infarction patients 2. Type 2 diabetics. Exclusion Criteria: 1. Patients undergoing coronary artery bypass grafting (CABG). 2. Severe valvular heart disease. 3. Contraindications of secondary medical preventive therapy for myocardial infarction, such as ß-blockers, angiotensin-converting enzyme inhibitors (ACEI)/ angiotensin-converting enzyme inhibitors (ARBs), antiplatelets, and statins. 4. Previously used SGLT2i. 5. Severe hepatic and renal insufficiency.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• SGLT2 inhibitor
According to whether SGLT2i was used

Locations
Country Name City State
China The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing

Sponsors (1)
Lead Sponsor Collaborator
Dongying Zhang

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary MACE cardiovascular death and heart failure and myocardial infarction 24months
Primary Heart failure readmission Heart failure readmission 24months
Secondary Recurrent myocardial infarction Recurrent myocardial infarction 24months
Secondary cardiovascular death cardiovascular death 24months
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A